| Product Form | HCA212G: A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL phage display library, expressed in E. coli The antibody is tagged with a V5 tag and a double extended Strep-tag (SAWSHPQFEKGGGSGGGSGGSAWSHPQFEK). |
|---|---|
| Preservative Stabilisers | 0.09% Sodium Azide (NaN 3 ) |
| Immunogen | Infliximab |
| Regulatory | For research purposes only |
| Guarantee | 12 months from date of despatch |
| Product Type | Monoclonal Antibody |
| Clone | AbD17837 |
| Isotype | HuCAL Fab monovalent |
| Specificity | Infliximab |
| Preparation | StrepTactin affinity chromatography |
| Buffer Solution | Phosphate buffered saline |
| Approx. Protein Concentrations | HCA212G: Antibody concentration 1.0 mg/ml |
| Source | E.coli |
| Synonyms | Remicade |
| Affinity | The monovalent intrinsic affinity of this antibody is K D = 3.2 nM as measured by real time, label-free molecular interaction analysis on immobilized infliximab. |
Answer:No. It is a monovalent recombinant human Fab with V5 and extended Strep tags.
Answer:Infliximab, a TNF-alpha-neutralizing monoclonal antibody.
Answer:1 mg.
Human Anti-Infliximab Antibody clone AbD17837 is a recombinant monovalent Fab reagent for immunoassays involving the TNF-alpha-binding therapeutic antibody infliximab. Unlike full-length human IgG1 anti-drug antibodies, this reagent consists of an antigen-binding fragment with a lambda light chain and engineered detection tags. Its V5 and extended Strep-tag features support tag-based detection in ELISA methods. The antibody recognizes infliximab and can interfere with infliximab binding to tumor necrosis factor alpha, enabling inhibitory binding assays and pharmacokinetic assay development. Use suitable capture and detection reagents to distinguish bound drug from free analyte and to minimize background caused by sample immunoglobulins. Validate standard-curve response, dilution linearity and recovery in the actual sample matrix before interpreting drug concentration results. This purified human Fab is produced in E. coli and supplied in phosphate-buffered saline. The 1 mg pack is not equivalent to the smaller 0.1 mg format or a complete IgG antibody.
Unless otherwise stated, the minimum order amount is USD 1,000.
For orders below USD 1,000, an additional handling fee may apply, or we may arrange local delivery / local handover where available.
All quotations are subject to final confirmation, including product availability, lead time, batch information, shipping cost, and applicable export or handling requirements.
For quotation requests, please send an RFQ from website or contact:
Please send inquiries directly to us in the “To” field. Emails sent via BCC, mass mailing, or with unrelated recipients may be automatically filtered and will not be processed.
| Acknowledgements |
|---|
| This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details. Remicade is a trademark of Janssen Biotech Inc. Inflectra is a trademark of Hospira, a Pfizer Company. RENFLEXIS is a trademark of Merck Sharp & Dohme Corp. |
| Licensed Use | For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad. |
|---|